Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -650.71% is 481% below its 5-year average of -112.09%, near the low end of its 5-year range (-1006.56%–461.63%).
81.96% below its 12-month average of -357.61%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-03-31): -56.15%.
EBITDA MARGIN
-650.71%
EBITDA MARGIN AVG TTM
-357.61%
EBITDA MARGIN AVG 3Y
-166.20%
EBITDA MARGIN AVG 5Y
-112.09%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-81.96%
CURRENT VS 3Y AVG
-291.53%
CURRENT VS 5Y AVG
-480.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
China SXT Pharmaceuticals, Inc.
Market Cap
$667469.00
EBITDA Margin
-650.71%
TTM Avg
-357.61%
3Y Avg
-166.20%
5Y Avg
-112.09%
Market Cap
$545796.00
EBITDA Margin
-18836.70%
TTM Avg
-9969.53%
3Y Avg
-5254.43%
5Y Avg
-4229.16%
Market Cap
$518606.00
EBITDA Margin
-8567.94%
TTM Avg
-8572.17%
3Y Avg
-8860.20%
5Y Avg
-7239.32%
Market Cap
$824550.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$835994.00
EBITDA Margin
-1.14%
TTM Avg
1.51%
3Y Avg
-2.34%
5Y Avg
-2.59%
Market Cap
$838843.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$868077.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | $667469.00 | -650.71% | -357.61% | -166.20% | -112.09% |
| CDT Equity Inc. (CDT)vs › | $716854.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | -18836.70% | -9969.53% | -5254.43% | -4229.16% |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | -8567.94% | -8572.17% | -8860.20% | -7239.32% |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | -1.14% | 1.51% | -2.34% | -2.59% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
Gross Margin
N/A
EBITDA Margin
-650.7%
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -56.15% |
| 2025-12-31 | -145.15% |
| 2025-09-30 | -1006.56% |
| 2025-03-31 | -222.56% |
| 2024-12-31 | -222.56% |
| 2024-09-30 | -68.68% |
| 2024-06-30 | -68.68% |
| 2024-03-31 | 8.36% |
| 2023-12-31 | 461.63% |
| 2023-09-30 | -514.73% |
| 2023-06-30 | -984.08% |
| 2023-03-31 | -205.60% |
| 2022-12-31 | -565.49% |
| 2022-09-30 | -90.66% |
| 2022-06-30 | -86.11% |
| 2022-03-31 | -24.09% |
| 2021-12-31 | -137.44% |
| 2021-09-30 | -54.69% |
| 2021-06-30 | -263.27% |
| 2021-03-31 | -44.00% |
| 2020-12-31 | 3.80% |
| 2020-09-30 | 34.88% |
| 2020-06-30 | 34.88% |
| 2020-03-31 | -25.83% |
| 2019-12-31 | -47.36% |
| 2019-09-30 | 199.99% |
| 2019-06-30 | -2.71% |
| 2019-03-31 | 16.94% |
| 2018-12-31 | 16.94% |
| 2018-09-30 | 36.41% |
| 2018-06-30 | 36.41% |
| 2018-03-31 | 23.02% |
| 2017-12-31 | 25.63% |
| 2017-09-30 | 28.50% |
| 2017-06-30 | 28.50% |
| 2017-03-31 | 45.35% |
